- The 8 States Most Likely to Legalize Marijuana Next
- Behind Russia's Current Crisis: It's Not the Ruble, It's Putin
- Would you invest in the U.S. Postal Service?
- Why Jim Cramer Says it Could be Too Late to Enter the Stock Market Rally Now
- Apple (AAPL) Stock Declining Today Amid Allegations of Poor Working Conditions in China
Options expert Tony Pelz says options are the best way to trade Ziopharma's looming palifosamide data.
Options expert Tony Pelz offers investors a way to use options to trade Dynavax's upcoming FDA decision.
A new options trade for Alexza going into an FDA drug approval decision.
Contributor Tony Pelz offers an options trade for those who believe Amicus shares are going higher.
How to use options to play a possible run-up in Dynavax prior to the FDA's approval decision.
Options wizard Tony Pelz suggests another way to trade Exelixis's FDA drug approval decision.
Tony Pelz offers a short-term options trade to take advantage of end-of-year selling in Eli Lilly.
How to play the high-risk release of results from Ziopharm's phase III study.
Options guru Tony Pelz offers options trades for those who want to protect their Sarepta profits.
Biotech options expert Tony Pelz recommends a bullish options trade for the Oct. 16 Gattex FDA panel.